MX2010011012A - Inmunoterapia en mucosas, especifica de alergeno, con dosificacion inicial despues de inicio de estacion de polen. - Google Patents

Inmunoterapia en mucosas, especifica de alergeno, con dosificacion inicial despues de inicio de estacion de polen.

Info

Publication number
MX2010011012A
MX2010011012A MX2010011012A MX2010011012A MX2010011012A MX 2010011012 A MX2010011012 A MX 2010011012A MX 2010011012 A MX2010011012 A MX 2010011012A MX 2010011012 A MX2010011012 A MX 2010011012A MX 2010011012 A MX2010011012 A MX 2010011012A
Authority
MX
Mexico
Prior art keywords
allergen
administration
seasonal
dosage form
dose
Prior art date
Application number
MX2010011012A
Other languages
English (en)
Spanish (es)
Inventor
Eike Gunther Wuestenberg
Eckhard-Carl Albrecht Puchert
Original Assignee
Alk Abello As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39809974&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010011012(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alk Abello As filed Critical Alk Abello As
Publication of MX2010011012A publication Critical patent/MX2010011012A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2010011012A 2008-04-11 2009-04-08 Inmunoterapia en mucosas, especifica de alergeno, con dosificacion inicial despues de inicio de estacion de polen. MX2010011012A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4440108P 2008-04-11 2008-04-11
DKPA200800533 2008-04-11
PCT/EP2009/054186 WO2009124954A1 (en) 2008-04-11 2009-04-08 Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season

Publications (1)

Publication Number Publication Date
MX2010011012A true MX2010011012A (es) 2010-11-12

Family

ID=39809974

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010011012A MX2010011012A (es) 2008-04-11 2009-04-08 Inmunoterapia en mucosas, especifica de alergeno, con dosificacion inicial despues de inicio de estacion de polen.

Country Status (12)

Country Link
US (2) US9248097B2 (enExample)
EP (1) EP2265285B1 (enExample)
JP (2) JP5618981B2 (enExample)
CN (1) CN102014954A (enExample)
AU (1) AU2009235490B2 (enExample)
BR (1) BRPI0911433A2 (enExample)
CA (1) CA2720455A1 (enExample)
DE (1) DE202008006598U1 (enExample)
EA (1) EA019202B1 (enExample)
ES (1) ES2406391T3 (enExample)
MX (1) MX2010011012A (enExample)
WO (1) WO2009124954A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047793A1 (en) * 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
DE202008006598U1 (de) * 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
MX2013003817A (es) 2010-10-15 2013-05-01 Alk Abello As Supresion de una respuesta inmunologica de hipersensibilidad con antigeno no relacionado derivado de material de fuente de alergeno.
US20120100163A1 (en) * 2010-10-15 2012-04-26 Alk-Abello A/S Suppression of a type 1 hypersensitivity immune response with an unrelated antigen
EP2681555B1 (en) 2011-02-25 2020-04-08 Benaroya Research Institute Detection of an allergic disorder
JP2012240978A (ja) * 2011-05-20 2012-12-10 Nitto Denko Corp 医薬組成物及びゼリー状製剤
JP2012240975A (ja) * 2011-05-20 2012-12-10 Nitto Denko Corp 医薬組成物及びゼリー状製剤
EP2804613A4 (en) 2012-01-16 2015-12-09 Elizabeth Mckenna COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEPATORY ILLNESSES AND DISORDERS
US12268718B2 (en) 2012-01-16 2025-04-08 Labyrinth Holdings Llc Control of cellular redox levels
US20140086849A1 (en) 2012-09-21 2014-03-27 Elizabeth McKenna Naturally-Occurring CpG Oligonucleotide Compositions and Therapeutic Applications Thereof
CN104755495A (zh) 2012-08-21 2015-07-01 赛诺菲 通过施用il-4r拮抗剂治疗或预防哮喘的方法
RU2698907C2 (ru) 2012-09-07 2019-09-02 Ридженерон Фармасьютикалз, Инк. Способы лечения атопического дерматита с помощью антагониста il-4r
TWI633891B (zh) 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
MX376691B (es) 2014-02-28 2025-03-07 Regeneron Pharma Composición farmaceutica que comprende un antagonista de il-4r para tratar una infección cutánea.
KR20230158131A (ko) 2014-11-14 2023-11-17 사노피 바이오테크놀로지 Ｉｌ-4ｒ 길항제의 투여에 의한, 비용종을 동반한 만성 부비동염의 치료 방법
PT3506931T (pt) 2016-09-01 2024-08-21 Regeneron Pharma Métodos de prevenção ou de tratamento da alergia mediante a administração de um antagonista de il-4r
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
KR102694419B1 (ko) 2017-10-30 2024-08-09 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
SG11202009371WA (en) 2018-05-13 2020-10-29 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r inhibitor
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
US12398212B2 (en) 2019-07-16 2025-08-26 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
CN114173819A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法
CN114173816A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗特应性皮炎的方法
EP4513185A1 (en) * 2023-08-22 2025-02-26 Luxembourg Institute of Health (LIH) Early response biomarkers for allergen immunotherapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK137992D0 (da) 1992-11-13 1992-11-13 Alk Lab As Fremgangsmaade til paavisning af et immunologisk aktivt stof i en proeve under anvendelse af et maerkningsstof
JPH0959179A (ja) * 1995-08-28 1997-03-04 Japan Tobacco Inc スギ花粉症予防性を有する口腔衛生剤
DK1062341T3 (da) 1998-03-16 2008-11-03 Alk Abello As Muterede rekombinante allergener
FR2778244B1 (fr) 1998-04-30 2000-07-13 Univ Joseph Fourier Procede d'excitation d'une cavite optique pour la detection de gaz a l'etat de traces
CZ20031653A3 (en) 2000-11-16 2004-03-17 Alk-Abelló A/S Mutant allergens
CA2486112A1 (en) 2002-05-16 2003-11-27 Alk Abello A/S Allergen mutants
WO2004047793A1 (en) * 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
EP1718331A4 (en) 2004-02-06 2009-11-11 Greer Lab Inc METHOD AND COMPOSITIONS FOR DOSING ALLERGENS
EP1718974A2 (en) * 2004-02-26 2006-11-08 Alk-Abell A/S Method of evaluating the therapeutic potential of a vaccine for mucosal administration
US20060115499A1 (en) 2004-09-27 2006-06-01 Alk-Abello A/S Liquid allergy vaccine formulation for oromucosal administration
ES2344915T3 (es) * 2004-11-10 2010-09-09 Alk-Abello A/S Procedimiento de tratamiento preventivo de alergia por administracion mucosal de una vacuna de alergia.
ATE468135T1 (de) 2004-11-10 2010-06-15 Alk Abello As Verfahren für die präventive behandlung von allergien durch verabreichung einer allergie- vakzine auf die schleimhäute
CN101098711A (zh) * 2005-01-07 2008-01-02 阿尔克-阿贝洛有限公司 通过口粘膜施用变态反应疫苗预防性治疗变态反应的方法
US20060210590A1 (en) * 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
US20090155351A1 (en) 2005-10-04 2009-06-18 Alk-Abello A/S Solid Vaccine Formulation
CA2628226A1 (en) 2005-11-04 2007-05-10 Alk-Abello A/S Use of a liquid allergy vaccine formulation for oromucosal administration
DE202007004567U1 (de) 2007-03-28 2007-10-11 Alk-Abelló A/S Verwendung einer adjuvierten Allergievakzinformulierung zur parenteralen Verabreichung
AU2008231722B2 (en) * 2007-03-28 2013-09-12 Alk-Abello A/S Use of an adjuvanted allergy vaccine formulation for parenteral administration
DE202008006598U1 (de) * 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung

Also Published As

Publication number Publication date
BRPI0911433A2 (pt) 2016-07-26
CN102014954A (zh) 2011-04-13
EP2265285A1 (en) 2010-12-29
DE202008006598U1 (de) 2008-10-02
JP2011516521A (ja) 2011-05-26
US20140127298A1 (en) 2014-05-08
EP2265285B1 (en) 2013-03-20
WO2009124954A1 (en) 2009-10-15
AU2009235490A1 (en) 2009-10-15
US9248097B2 (en) 2016-02-02
AU2009235490B2 (en) 2013-10-24
US20110142934A1 (en) 2011-06-16
JP5618981B2 (ja) 2014-11-05
ES2406391T3 (es) 2013-06-06
EA019202B1 (ru) 2014-01-30
CA2720455A1 (en) 2009-10-15
EA201071182A1 (ru) 2011-06-30
JP2015013891A (ja) 2015-01-22
HK1147946A1 (en) 2011-08-26

Similar Documents

Publication Publication Date Title
AU2009235490B2 (en) Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season
EP2436395B1 (en) An allergen dosage form
HK1200019A1 (en) Use of a liquid allergy vaccine formulation for oromucosal administration
MXPA05009079A (es) Forma de dosificacion que tiene una matriz de sacarido.
AU2008231722B2 (en) Use of an adjuvanted allergy vaccine formulation for parenteral administration
HK1147946B (en) Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season
EP1974745B1 (en) Use of an adjuvanted allergy vaccine formulation for subcutaneous administration
CN101340892A (zh) 用于口腔粘膜给药的液体变态反应性疫苗制剂的用途
HK1110773B (en) Use of a liquid allergy vaccine formulation for oromucosal administration
HK1087008B (en) An allergen dosage form
HK1147215A (en) An allergen dosage form

Legal Events

Date Code Title Description
FG Grant or registration